Shares of Antares Pharma, Inc. (NASDAQ:ATRS) have received an average rating of “Buy” from the six research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $5.67.
ATRS has been the subject of a number of research reports. HC Wainwright raised their price objective on Antares Pharma from $4.50 to $5.00 and gave the stock a “buy” rating in a research report on Monday. Zacks Investment Research lowered Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, May 10th.
NASDAQ ATRS traded up $0.04 during trading on Thursday, reaching $4.08. 13,104 shares of the company’s stock were exchanged, compared to its average volume of 1,134,523. Antares Pharma has a fifty-two week low of $2.53 and a fifty-two week high of $5.07. The firm has a market capitalization of $688.70 million, a PE ratio of 67.34 and a beta of 1.44. The company has a current ratio of 2.47, a quick ratio of 2.08 and a debt-to-equity ratio of 0.53. The company’s fifty day simple moving average is $3.96 and its 200-day simple moving average is $3.91.
In other news, Director Thomas J. Garrity sold 50,000 shares of the firm’s stock in a transaction dated Thursday, March 11th. The stock was sold at an average price of $4.28, for a total transaction of $214,000.00. Following the completion of the sale, the director now directly owns 274,406 shares of the company’s stock, valued at approximately $1,174,457.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert F. Apple sold 491,960 shares of the firm’s stock in a transaction that occurred on Thursday, February 18th. The shares were sold at an average price of $5.00, for a total value of $2,459,800.00. Following the completion of the transaction, the chief executive officer now directly owns 2,563,033 shares in the company, valued at $12,815,165. The disclosure for this sale can be found here. Insiders have sold a total of 602,281 shares of company stock valued at $2,973,021 over the last ninety days. Company insiders own 5.90% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Perkins Capital Management Inc. raised its stake in shares of Antares Pharma by 112.2% in the 4th quarter. Perkins Capital Management Inc. now owns 480,783 shares of the specialty pharmaceutical company’s stock valued at $1,918,000 after acquiring an additional 254,250 shares in the last quarter. BlackRock Inc. raised its stake in shares of Antares Pharma by 2.9% in the 4th quarter. BlackRock Inc. now owns 11,826,153 shares of the specialty pharmaceutical company’s stock valued at $47,186,000 after acquiring an additional 336,315 shares in the last quarter. Virginia Retirement Systems ET AL bought a new position in shares of Antares Pharma in the 4th quarter valued at approximately $164,000. Rhumbline Advisers raised its stake in shares of Antares Pharma by 7.6% in the 4th quarter. Rhumbline Advisers now owns 280,816 shares of the specialty pharmaceutical company’s stock valued at $1,120,000 after acquiring an additional 19,855 shares in the last quarter. Finally, IndexIQ Advisors LLC raised its stake in shares of Antares Pharma by 11.5% in the 4th quarter. IndexIQ Advisors LLC now owns 88,748 shares of the specialty pharmaceutical company’s stock valued at $354,000 after acquiring an additional 9,163 shares in the last quarter. 39.92% of the stock is currently owned by institutional investors and hedge funds.
Antares Pharma Company Profile
Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.